Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Institutional investors buy $63.3mm of Supernus debt

Executive Summary

Supernus Pharmaceuticals (drug delivery technologies for selection, optimization, and formulation of epilepsy, anti-anxiety, and other neurology candidates) has netted $63.3mm by selling 16% secured, nonconvertible, nonrecourse promissory notes due April 15, 2024, to TCD Royalty Sub. At its option, the company may redeem the notes. As part of the transaction, Royalty Syb acquired the future royalty streams on Oracea and Sanctura XR. Should the combined royalties for Supernus's partnered products Oracea and Sanctura XR exceed the interest payments and certain expenses in any given quarter, the excess money will be applied to the principle until the notes are paid in full.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies